Vertex Pharmaceuticals (VRTX) saw its stock price plummet 6.92% in Tuesday's trading session following disappointing first-quarter results and a downgrade from a major investment firm. The biotechnology company, known for its cystic fibrosis treatments, faced headwinds that have raised concerns among investors.
The company reported Q1 revenue of $2.77 billion, falling short of analyst expectations of $2.85 billion according to data compiled by LSEG. Additionally, Vertex's quarterly adjusted profit of $4.06 per share came in below the estimated $4.32. The revenue decline was particularly noticeable in Russia, where Vertex's intellectual property rights are being violated due to an unauthorized copy of its cystic fibrosis drug Trikafta.
Adding to the pressure, Leerink Partners downgraded Vertex Pharmaceuticals from Outperform to Market Perform, reducing their price target from $550 to $503. This move reflects growing caution among analysts about the company's near-term prospects. Despite these challenges, Vertex slightly raised the low end of its full-year 2025 revenue forecast range to $11.85 billion from $11.75 billion, while maintaining the higher end at $12 billion. The stock's performance has been lackluster year-to-date, down approximately 24% prior to this latest decline.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.